Express News | US FDA: Revoked Emergency Use Authorization for GSK and Vir Biotechnology's Sotrovimab as of Dec 13 - Website
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Vir Gets FDA Breakthrough Therapy Status for Two Drugs
Express News | Vir Biotechnology Inc - Phase 3 Eclipse Program to Begin in First Half of 2025
Express News | Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
my friend
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}